[Prevention and therapy of gastroduodenal stress hemorrhage in intensive care patients using the histamine H2-receptor antagonist cimetidine].
In our intensive care unit we were able to prevent almost all bleedings from stress ulcerations in patients with insufficiency of various organs by administering the H2-receptor blocker, cimetidine, in doses of 200 mg eight times per day. However, stres ulcer bleedings occurred in 14% of those patients also suffering from a sepsis. At lower doses of cimetidine, the rate of bleeding was comparable to that encountered in patients treated with antacids, i.e. 12.5% patients with multiple organ insufficiency and 42.7% with sepsis. Cimetidine did not show any therapeutic effect in case of bleeding which led to a significant fall in hemoglobin concentration.
D002927:Cimetidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D007362:Intensive Care Units; D010438:Peptic Ulcer Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D013312:Stress, Physiological
D006146:Guanidines; D002927:Cimetidine
Zur Prophylaxe und Therapie gastroduodenaler Stressblutungen bei Intensivpatienten mit dem Histamin-H2-Receptoren-Antagonisten Cimetidin.